PolyPid (FRA:2PV) Interest Coverage: N/A (As of Mar. 2026)


FRA:2PV PolyPid Ltd FRA:2PV
14 GF Score
Price €3.99
! 1 Warning Sign
View Full Analysis

What is PolyPid Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. PolyPid's Operating Income for the three months ended in Mar. 2026 was €-6.71 Mil. PolyPid's Interest Expense for the three months ended in Mar. 2026 was €0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for PolyPid's Interest Coverage or its related term are showing as below:


FRA:2PV's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


PolyPid  (FRA:2PV) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


PolyPid Interest Coverage Related Terms


PolyPid Interest Coverage Historical Data

* Premium members only.

The historical data trend for PolyPid's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

PolyPid Interest Coverage Chart

PolyPid Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt 0.00 0.00 0.00 0.00

PolyPid Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 N/A N/A N/A

FRA:2PV vs LONA, ANIX, SGMO: Interest Coverage Comparison

For the Biotechnology subindustry, PolyPid's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPid Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PolyPid's Interest Coverage distribution charts can be found below:

* The bar in red indicates where PolyPid's Interest Coverage falls into.


FRA:2PV
14GF Score
PolyPid Ltd FRA:2PV
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPid Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PolyPid's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, PolyPid's Interest Expense was €-0.75 Mil. Its Operating Income was €-28.15 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.55 Mil.

PolyPid did not have earnings to cover the interest expense.

PolyPid's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, PolyPid's Interest Expense was €0.00 Mil. Its Operating Income was €-6.71 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.33 Mil.

GuruFocus does not calculate PolyPid's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


PolyPid Business Description

Other Exchanges PYPD:USA
Address 18 Hasivim Street, Petach Tikva, ISR, 495376
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
14GF Score

Get the complete analysis for FRA:2PV

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.99
Price